Synapse - Manjit Bains

Results (120)

FDG-PET scan after induction chemotherapy for esophageal squamous cell cancer (ESCC) to predict for outcomes after chemoradiation (chemoRT) and to guide salvage chemotherapy during RT

Meeting Abstract

Ku, G. Y.; Janjigian, Y. Y.; Kriplani, A.; Ong, L.; Rusch, V. W.; Bains, M. S.; Rizk, N. P.; Sarkaria, I. S.; Capanu, M.; Goodman, K. A.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Phase I/II study of paclitaxel plus ifosfamide followed by high-dose paclitaxel, ifosfamide, and carboplatin with autologous stem cell reinfusion for salvage treatment of germ cell tumors

Meeting Abstract

Feldman, D. R.; Glezerman, I.; Patil, S.; Van Alstine, L.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M.; Reich, L.; more...
Biology of Blood and Marrow Transplantation (2014)

Fulltext@MSK | Save

Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma

Journal Article

Gerber, N.; Ilson, D. H.; Wu, A. J.; Janjigian, Y. Y.; Kelsen, D. P.; Zheng, J.; Zhang, Z.; Bains, M. S.; Rizk, N.; Rusch, V. W.; more...
Diseases of the Esophagus (2014)

Fulltext@MSK | Save

Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Hu, J.; Dorff, T. B.; Patil, S.; Van Alstine, L. J.; Momen, L.; Carousso, M.; Hughes, A.; Snively-Solomon, J.; Ketchens, C.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT)

Meeting Abstract

Jia, X.; Feldman, D. R.; Glezerman, I.; Van Alstine, L. J.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M. S.; Reich, L.; more...
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)